Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzira vaccine immunogenicity and safety in healthy adults and older adults
NCT01857297Phase 4Completed
- Sponsor
- CSL Seqirus
- Start
- May 2013
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Afluria in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoints: Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre at 21 days, Geometric Mean Fold Increase in Antibody Titre at 21 days and 1 more. Started May 2013; status: completed.
02
Drugs
Afluria
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01857297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01857297.